期刊文献+

心脏术后患者的药学监护 被引量:1

Pharmaceutical Care for the Patient after Cardiac Surgery
下载PDF
导出
摘要 目的:临床药师参与临床药物治疗,对患者进行药学监护。方法:以一位心脏术后患者为例,临床药师参与药物治疗方案的制订,分析患者所用相关药物,跟踪其治疗效果及不良反应,对药物治疗过程进行综合评估。结果:患者的各项指标趋于正常。结论:临床药师的参与使药物治疗更趋合理,在达到治疗目标的同时,可减少药物的不良反应,有利于提高临床的药物治疗水平。 Objective: Clinical pharmacists involved in clinical drug therapy and pharmaceutical care for patients and cooperated with clinicians in order to promote rational drug use in clinics. Method: Clinical pharmacists involved in therapeutic scheme making, medication analysis and evaluation, such as anticoagulant drugs, antibiotics, cardiac drags, and diuretics, etc. used in the patient after cardiac surgery, and made a comprehensive drug treatment assessment including effectiveness and adverse reactions in whole therapy process. Result: All the indices of the patient trended toward normal. Conclusion : The participation of clinical pharmacists in clinical treatment team and clinical practice can make drug treatment more rational with therapeutic goal reached and adverse drug reactions reduced to improve the level of clinical drug treatment.
出处 《中国药师》 CAS 2011年第4期526-528,共3页 China Pharmacist
关键词 临床药师 心脏术后患者 药学监护 Clinical pharmacists Patient after cardiac surgery Pharmaceutical care
  • 相关文献

参考文献5

  • 1邵宏.美国临床药师培养模式初探[J].中国新药杂志,2008,17(1):79-82. 被引量:53
  • 2Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anti coagulation related outcomes during warfarin therapy[J]. JAMA,2002,287(13) :1690-1698.
  • 3Margaglione M, Colaizzo D, Andrea GD ,et al. Genetic modulationo for alanticoagulation with warfarin [J]. Thromb Haemost, 2000,84 ( 5 ) :775-778.
  • 4Voora D, Linder MW. Prospective dosing of Warfarin based on cyto- chrome genotype [ J ]. Thromb Haemost,2005,93 (4) :700-705.
  • 5童荣生,陈岷,黄晓波,杨勇,李刚,龙恩武.循证药学在碳青霉烯类药物临床使用中的应用[J].中国药师,2009,12(11):1606-1609. 被引量:10

二级参考文献11

  • 1Norrby SR, Newen PA, Faulkner KL. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem [ J]. J Antimicrob Chemother, 1995,36 ( Suppl A) :207-223.
  • 2Non'by SR, Kathleen M. Golden. Safety profile of meropenem a review of neraly 5000 patients treated with meropenem[ J ]. Scand J Infec Dis. 1999,31:3-10.
  • 3Steven J, Canthy E, Emmas C, et al. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections [ J ]. Current medical research and opinion ,2005, 21, (5) :785 - 794.
  • 4Linden P. Safety profile of merepenem an updated review of over 6000 patients treated with Meropenem[ J]. Drug Safety,2007,30 (8) : 657--668.
  • 5Hou F, Li JT, Wu GP. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections [ J ]. Chim Med J ( Engl) ,2002,115(12) :1849-1854.
  • 6Cox CE,Holloway WJ,Geckler RW. A muhicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients[ J ]. Clin Infect Dis, 1995,21 ( 1 ) :86-92.
  • 7Garau J,Blanquer J,Cobo L,et al. Prospective, randomised, muhieentro study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections[J]. Eur J Clin Microbiol Infect Dis,1997 ,16( 11 ) :789-796.
  • 8Sutep J, Somchai S, Jarurat P, et al. Comparison of the pharmacodynamics of meropenemin patients with ventilator-Associated pneumonia following administration by 3-hour infusionor bolus injection [ J ]. Antimicrobicd agents and chemotherapy,2005,49(4) :1337-1339.
  • 9KIEL PJ, MCCORD AD. Collaborative practice agreement for diabetes management[J]. Am J Health Syst Pharm, 2006, 63(3) : 209 - 210.
  • 10AACP. Academic pharmacy's vital statistics[ EB/OL ]. [2007 -07 - 01 ]. www. aacp. org.

共引文献61

同被引文献21

  • 1吴安华,徐秀华.癌症并中性粒细胞减少病人的抗菌药物应用指南[1][J].中国感染控制杂志,2002,1(1):75-79. 被引量:9
  • 2李苏宜,许莉,王冬青,高志刚,王春燕.顺铂的不同给药方式与肾毒性的研究[J].实用肿瘤学杂志,1994,8(3):46-47. 被引量:1
  • 3NCCN clinical practice guidelines in oncology( Small cell lung canc- er) [EB/OL]. http://www, nccn. org/professionals/physician_gls/f_ guidelines, asp, 2012 -07 -06/2013 -03 - 10.
  • 4Koda-Kimble MA, Lloyd YY, et al. Applied Therapeutics The Clinical Use of Drugs[M].北京:人民卫生出版社,2007.89.
  • 5Andreas H, Bengt B, Roy B, et al. Irinotecan plus carboplatin ver- sus oral etoposide plus carboplatin in extensive small-cell lung canc- er : a randomized phase III trial [ J ]. J Clin Oncol,2008,26 ( 26 ) : 4261-4267.
  • 6Alberto ME, Lucas MF,Pavelka M,et al. The second generation anti- cancer drug Nedaplatin: a theoretical investigation on the hydrolysis mechanism[J]. J Phys Chem B,2009,113(43) :144-173.
  • 7Kawai Y, Taniuehi S, Okahara S, et al. Relationship between eisplatin or nedaptatin-indueed nephrotoxieity and renal aecumulation[J]. Biol Pharm Bull, 2005,28 ( 8 ) : 1385-1388.
  • 8Yu SY, Jiang ZF, Zhang L,et al. Chinese expert consensus state- ment on clinical diagnosis and treatment of malignant tumor bone me- tastasis and bone related diseases [ J ]. Chinese-German Journal of Clinical Oneology January, 2010,9 : 1-12.
  • 9Reid IR, Gamble GD, Mesenbrink P, et al. Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid [ J]. J Clin Endocrinol Metab, 2010, 95 (9) :4380-4387.
  • 10Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study[J]. CMAJ, 2012, 184(8) :431-434.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部